Emmanuelle Di TomasoPhD
Dr. di Tomaso obtained her Ph.D. in Clinical Chemistry at the Institute of Child Health, University College, London, UK. She first focused her career in academia spending 11 years at the Massachusetts General Hospital studying angiogenesis and vascular biology in the context of several cancers. This included the first successful implementation of anti-angiogenic therapy to restore hearing in patients with NF2 acoustic neuroma.
She then spent 7 years at Novartis where she led the precision medicine strategy for multiple clinical programs in late development with a focus on the breast cancer portfolio (including PI3K and CDK4/6 inhibitors). She is currently Head of Translation Medicine at Syros Pharmaceuticals where she established and developed the Translational Medicine function to leverage precision medicine for two drug target candidates discovered by the Syros gene control discovery platform.